Munich Reinsurance Co Stock Corp in Munich Boosts Position in Gilead Sciences, Inc. $GILD

Key Points

• Munich Re increased its stake in Gilead by 8.2% to 657,973 shares, making Gilead ~2.0% of Munich Re's portfolio and valuing that holding at about $81.05 million (roughly 0.05% ownership of Gilead).
• Insider selling has been notable recently — CEO Daniel O'Day sold 115,640 shares (about $17.35M) and insiders have sold 178,640 shares in the last 90 days, leaving corporate insiders with only 0.30% ownership.
• Fundamentals and outlook — Gilead beat quarterly estimates (EPS $1.86 vs $1.83; revenue $7.93B), set FY2026 guidance of $8.45–$8.85 EPS, raised its quarterly dividend to $0.82 (2.5% yield), and analysts have pushed average price targets to $157.35 with a consensus "Moderate Buy."

Munich Reinsurance Co Stock Corp in Munich raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 657,973 shares of the biopharmaceutical company's stock after buying an additional 49,868 shares during the quarter. Gilead Sciences makes up about 2.0% of Munich Reinsurance Co Stock Corp in Munich's investment portfolio, making the stock its 8th largest holding. Munich Reinsurance Co Stock Corp in Munich owned about 0.05% of Gilead Sciences worth $81,049,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Invesco Ltd. lifted its stake in Gilead Sciences by 12.0% in the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company's stock valued at $1,680,505,000 after buying an additional 1,618,453 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Gilead Sciences by 4.2% during the third quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company's stock valued at $1,133,376,000 after purchasing an additional 414,454 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Gilead Sciences by 5.9% during the third quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company's stock valued at $793,506,000 after purchasing an additional 400,002 shares in the last quarter. Nordea Investment Management AB raised its stake in shares of Gilead Sciences by 16.5% during the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company's stock valued at $630,056,000 after purchasing an additional 726,101 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of Gilead Sciences by 3,763.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company's stock valued at $518,368,000 after purchasing an additional 4,113,999 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 115,640 shares of the business's stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the sale, the chief executive officer owned 613,912 shares of the company's stock, valued at approximately $92,086,800. The trade was a 15.85% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the sale, the insider directly owned 120,288 shares of the company's stock, valued at approximately $18,577,278.72. The trade was a 18.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 178,640 shares of company stock valued at $26,691,550 in the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Down 2.4%

NASDAQ:GILD opened at $130.40 on Friday. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The stock's 50-day moving average is $142.44 and its two-hundred day moving average is $132.02. The stock has a market cap of $161.86 billion, a PE ratio of 19.26, a price-to-earnings-growth ratio of 1.76 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to analysts' expectations of $7.68 billion. During the same quarter in the previous year, the business posted $1.90 EPS. The business's revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 8.63 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were paid a dividend of $0.82 per share. This is a boost from Gilead Sciences's previous quarterly dividend of $0.79. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences's dividend payout ratio (DPR) is presently 48.45%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on GILD. Daiwa Securities Group lifted their price objective on shares of Gilead Sciences from $129.00 to $161.00 and gave the company an "outperform" rating in a research note on Wednesday, February 25th. Argus lifted their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the company a "buy" rating in a research note on Thursday, February 19th. TD Cowen lifted their price objective on shares of Gilead Sciences from $145.00 to $160.00 and gave the company a "buy" rating in a research note on Wednesday, February 11th. Oppenheimer lifted their price objective on shares of Gilead Sciences from $128.00 to $165.00 and gave the company an "outperform" rating in a research note on Wednesday, February 11th. Finally, Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an "overweight" rating in a research note on Wednesday, February 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $157.35.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.